Shorts collapsed the stock price making credit markets inaccessible for management. Should you direct anger at such manipulation rather than blaming management which brought us to cusp of global approval? Yes.
I am glad angel investors continue to see value in the company. Obviously post approval we will be in a different situation as institutional investors and credit markets will be much easier to access on favorable terms.
I am very excited about the last two months of 2024 as they should being monumental news for Northwest Biotherapeutics shareholders.